Depomed, Inc.

Cygnus, Inc.

Teikoku Pharma Usa, Inc.

Ciba-geigy Corporation

Sage Therapeutics, Inc.

Other

Novartis Corporation

Animas Corporation

Animas Technologies, LLC

Alvine Pharmaceuticals, Inc.

St IP Holding Ag

Immunogenics LLC

Evecxia Therapeutics, Inc.

Principia Biopharma Inc.

Bret Berner

Sui Yuen Eddie Hou

Gloria Gusler

Michael J Tierney

Janet A Tamada

Russell O Potts

Michael D Garrison

Jenny Louie-Helm

Chia-Ming Chiang

Janan Jona

Adchara Pongpeerapat

John N Shell

Jianye Wen

Jutaro Shudo

Timothy Christian Dunn

Ronald T Kurnik

Amit K Jain

John W Shell

Paul Steven Watson

John Gregory Reid

Matthew J Lesho

Matthew John Siegel

Norman A Parris

Stephen Jay Kanes

Kathleen C Farinas

Kensuke Murata

Charles D Ebert

Theophilus Jones Gana

David Michael Goldstein

Corey Bloom

Mohammad Reza Masjedizadeh

Amit Jain

Cuiping Chen

Jian Wang

Lynn Kim

James J Doherty

Gerard C Mazzenga

Bomi Framroze

Michael Edward Grass

Casey Keith Jager

Mark Joseph Kastantin

John H Otte

Anthony Chris Garland

Xiaoling Li

Marilou S Cramer

Barbara-Jean Anne Bormann-Kennedy

Wu Lin

Jacob Pade Ramsoe Jacobsen

Micheline Markey

Jay Corey Bloom

Aimee Padua

Mei Chau

Romain Bachelard

Steven Minh Dinh

Steven Andrew Giannos

Ching Sieu Tay

Russell Haynes

Asha Sunkara

Carl A Pelzel

Philipp Nunn

Philip A Nunn

Gloria M Gusler

Sui Yuen Hou

Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.

Topical naloxone compositions and methods for using the same

This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid

A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.

5-hydroxytryptophan gastroretentive dosage forms

This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.

Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof. 

Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid

This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.

Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-l,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same

Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.

Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine

Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.

Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.

Dexmedetomidine transdermal delivery devices and methods for using the same

Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.

Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same

Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten.

Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance

Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.

Formulation for oral administration of proteins

Growing community of inventors

Half Moon Bay, CA, United States of America

Bret Berner